• metastatic/adv melanoma (mML)
• mML - (neo)adjuvant (NA)
• mML - NA - all population 9
• mML - NA - PDL1 positive 1
• mML - 1st line (L1)
• mML - L1 - all population 7
• mML - L1 - BRAF mutant 2
• mML - L1 - BRAF wild 3
• mML - 2nd line (L2)
• mML - L2 - all population 11
• mML - L2 - BRAF mutant 1
• mesothelioma (MS)

 

• immune chekpoint inhibitors
• anti-CTLA-4
• tremelimumab
• anti-PD-(L)1
• nivolumab based treatment
• nivolumab alone
• nivolumab followed by ipilimumab
• Immune checkpoint association
• nivolumab plus ipilimumab
• relatlimab plus nivolumab

• versus all
• vs chemotherapy
• vs Standard of Care (SoC)
• vs immune chekpoint inhibitors
• vs anti-CTLA-4
• vs ipilimumab based treatment
• vs ipilimumab alone
• vs ipilimumab followed by nivolumab
• vs anti-PD-(L)1
• vs nivolumab based treatment
• vs nivolumab alone
• vs Immune checkpoint association
• vs nivolumab plus ipilimumab

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

Pathology:  mML - L1 - all population;